Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05547399 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT05547399 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 43 participants.
The verdict
NCT05547399, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
Study to assess the relative bioavailability of zanubrutinib tablets compared to capsules and to evaluate the effects of food on the pharmacokinetics (PK) of the zanubrutinib tablet.
Interventions
- DRUG Zanubrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05547399
The ClinicalTrials.gov registry entry for NCT05547399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zanubrutinib is the first listed.
NCT05547399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05547399 about?
NCT05547399 is a clinical study titled "Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults". Study to assess the relative bioavailability of zanubrutinib tablets compared to capsules and to evaluate the effects of food on the pharmacokinetics (PK) of the zanubrutinib tablet.
What is the current status of trial NCT05547399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-06-07. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT05547399?
The interventions under investigation include: Zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT05547399?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.